OBJECTIVES: We aimed to determine adherence, virological, and immunological outcomes one year after starting a first combination antiretroviral therapy (ART) regimen. DESIGN: Observational; synthesis of administrative, laboratory, and pharmacy data. Antiretroviral regimens were divided into efavirenz, nevirapine, boosted protease inhibitor (PI), and single PI categories. Propensity scores were used to control for confounding by treatment assignment. Adherence was estimated from pharmacy refill records. SETTING: Veterans Affairs Healthcare System, all sites. PARTICIPANTS: HIV-infected individuals starting combination ART with a low likelihood of previous antiretroviral exposure. INTERVENTIONS: None. OUTCOMES: The proportion of antiretroviral prescriptions filled as prescribed, a change in log HIV-RNA, the proportion with log HIV-RNA viral suppression, a change in CD4 cell count. RESULTS: A total of 6394 individuals unlikely to have previous antiretroviral exposure started combination ART between 1996 and 2004, and were eligible for analysis. Adherence overall was low (63% of prescriptions filled as prescribed), and adherence with efavirenz (67%) and nevirapine (65%) regimens was significantly greater than adherence with boosted PI (59%) or single PI (61%) regimens (P < 0.001). Efavirenz regimens were more likely to suppress HIV-RNA at one year (74%) compared with nevirapine (62%), boosted PI (63%), or single PI (53%) regimens (all P < 0.001), and this superiority was maintained when analyses were adjusted for baseline clinical characteristics and propensity for treatment assignment. Efavirenz also yielded more favorable immunological outcomes. CONCLUSION: HIV-infected individuals initiating their first combination ART using an efavirenz-based regimen had improved virological and immunological outcomes and greater adherence levels.
OBJECTIVES: We aimed to determine adherence, virological, and immunological outcomes one year after starting a first combination antiretroviral therapy (ART) regimen. DESIGN: Observational; synthesis of administrative, laboratory, and pharmacy data. Antiretroviral regimens were divided into efavirenz, nevirapine, boosted protease inhibitor (PI), and single PI categories. Propensity scores were used to control for confounding by treatment assignment. Adherence was estimated from pharmacy refill records. SETTING: Veterans Affairs Healthcare System, all sites. PARTICIPANTS: HIV-infected individuals starting combination ART with a low likelihood of previous antiretroviral exposure. INTERVENTIONS: None. OUTCOMES: The proportion of antiretroviral prescriptions filled as prescribed, a change in log HIV-RNA, the proportion with log HIV-RNA viral suppression, a change in CD4 cell count. RESULTS: A total of 6394 individuals unlikely to have previous antiretroviral exposure started combination ART between 1996 and 2004, and were eligible for analysis. Adherence overall was low (63% of prescriptions filled as prescribed), and adherence with efavirenz (67%) and nevirapine (65%) regimens was significantly greater than adherence with boosted PI (59%) or single PI (61%) regimens (P < 0.001). Efavirenz regimens were more likely to suppress HIV-RNA at one year (74%) compared with nevirapine (62%), boosted PI (63%), or single PI (53%) regimens (all P < 0.001), and this superiority was maintained when analyses were adjusted for baseline clinical characteristics and propensity for treatment assignment. Efavirenz also yielded more favorable immunological outcomes. CONCLUSION:HIV-infected individuals initiating their first combination ART using an efavirenz-based regimen had improved virological and immunological outcomes and greater adherence levels.
Authors: R Scott Braithwaite; Kathleen A McGinnis; Joseph Conigliaro; Stephen A Maisto; Stephen Crystal; Nancy Day; Robert L Cook; Adam Gordon; Michael W Bridges; Jason F S Seiler; Amy C Justice Journal: Alcohol Clin Exp Res Date: 2005-07 Impact factor: 3.455
Authors: R S Braithwaite; S Shechter; M S Roberts; A Schaefer; D R Bangsberg; P R Harrigan; A C Justice Journal: J Antimicrob Chemother Date: 2006-10-05 Impact factor: 5.790
Authors: Christian Holkmann Olsen; Jose Gatell; Bruno Ledergerber; Christine Katlama; Nina Friis-Møller; Jonathan Weber; Andrzéj Horban; Schlomo Staszewski; Jens D Lundgren; Andrew N Phillips Journal: AIDS Date: 2005-02-18 Impact factor: 4.177
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Sue J Goldie; A David Paltiel; Milton C Weinstein; Elena Losina; George R Seage; April D Kimmel; Rochelle P Walensky; Paul E Sax; Kenneth A Freedberg Journal: Am J Med Date: 2003-12-01 Impact factor: 4.965
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Amalia Rodriguez-French; Jack Boghossian; Glenda E Gray; Jeffrey P Nadler; Arnaldo R Quinones; Gladys E Sepulveda; Judith M Millard; Paul G Wannamaker Journal: J Acquir Immune Defic Syndr Date: 2004-01-01 Impact factor: 3.731
Authors: Vincent Lo Re; Valerie Teal; A Russell Localio; Valerianna K Amorosa; David E Kaplan; Robert Gross Journal: Ann Intern Med Date: 2011-09-20 Impact factor: 25.391
Authors: Mhairi Maskew; Alana T Brennan; A Patrick MacPhail; Ian M Sanne; Matthew P Fox Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-09-27
Authors: Amin Khademi; Denis Saure; Andrew Schaefer; Kimberly Nucifora; R Scott Braithwaite; Mark S Roberts Journal: Value Health Date: 2015-11-12 Impact factor: 5.725
Authors: Raj K Medapalli; Chirag R Parikh; Kirsha Gordon; Sheldon T Brown; Adeel A Butt; Cynthia L Gibert; David Rimland; Maria C Rodriguez-Barradas; Chung-Chou H Chang; Amy C Justice; John Cijiang He; Christina M Wyatt Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Emily A Wang; Kathleen A McGinnis; Jessica B Long; Kathleen M Akgün; E Jennifer Edelman; David Rimland; Karen H Wang; Amy C Justice; David A Fiellin Journal: Am J Addict Date: 2015-02-06
Authors: Jason Kessler; Julie E Myers; Kimberly A Nucifora; Nana Mensah; Christopher Toohey; Amin Khademi; Blayne Cutler; Scott Braithwaite Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Ronald Scott Braithwaite; Kimberly A Nucifora; Christopher Toohey; Jason Kessler; Lauren M Uhler; Sherry M Mentor; Daniel Keebler; Timothy Hallett Journal: AIDS Date: 2014-01 Impact factor: 4.177
Authors: Seth C Kalichman; Tamar Grebler; Christina M Amaral; Megan McNerey; Denise White; Moira O Kalichman; Chauncey Cherry; Lisa Eaton Journal: J Gen Intern Med Date: 2012-10-12 Impact factor: 5.128